Reviva Pharmaceuticals Shares Tumble Following $9 Million Equity Offering

Reviva Pharmaceuticals Holdings Inc. witnessed a sharp decline in its share price after unveiling plans to raise $9 million through a new stock offering. Investor sentiment turned negative, primarily driven by concerns over the dilutive effect of the newly issued shares on existing equity.

The clinical-stage biopharmaceutical company has arranged to place 27 million shares at a price of $0.335 per share. The deal includes attached Series E and Series F warrants, each granting the right to purchase an additional share at the same price within five and twelve months, respectively. The market’s immediate and negative reaction highlights investor dissatisfaction with the significant potential dilution of their holdings.

Scheduled to close on September 22, 2025, the offering is being managed by sole placement... Read more...